Lyophilization is emerging as a key manufacturing stabilizer for antibody-drug conjugate (ADC) products across formulation and processing stages. A comprehensive scientific review outlines how freeze-drying and process analytics can protect complex ADC structures from instability during manufacturing. The review focuses on practical manufacturing constraints, emphasizing that ADC integrity depends on controlling degradation pathways during both formulation and downstream processing steps. It also highlights the role of advanced process analytics to detect and manage those failure modes. For development teams, the message is operational: lyophilization plus robust analytics may reduce batch-to-batch variability and preserve drug-to-antibody conjugate performance. The implications extend to supply-chain resiliency and scale-up planning for ADC programs that require consistent potency and stability throughout manufacturing and storage.